Quintiles' owners eye $750M in a stock sale; inVentiv recruits an eBay exec to run its ad biz;

> Quintiles ($Q) founder Dennis Gillings and three of the CRO's private equity owners are scaling back their stakes in the company through a stock sale, selling off more than $750 million in shares. The company plans to buy $250 million worth with the rest going to the public. News

> Catalent ($CTLT) has expanded its highly potent and cytotoxic clinical drug packaging capabilities with a new 6,000-square-foot facility in Kansas City, MO. More

> CRO conglomerate inVentiv Health has named former eBay executive Jeffrey Wilks to head up its internal advertising business. Item

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.